Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reviews Expansion of Client Base, Noting Unprecedented Number of License Agreements
Lexaria’s patented DehydraTECH technology improves taste, achieves higher absorption rates and promotes fast onset of bioactive compounds, including nicotine and cannabinoids Nine corporate licensees have signed a total of 11 definitive contracts to use DehydraTECH technology in innovative beverages, edibles and oral products Lexaria expects to experience unprecedented revenue growth as many of its clients plan aggressive rollouts and growth for their product lines Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is expanding its family of existing licensees and partners with an impressive lineup of new corporate licensees for use of Lexaria’s patented DehydraTECH…